Association between sepsis and retinopathy of prematurity: a systematic review and meta-analysis

Xiaofen Wang,1 Kun Tang,1,2 Ling Chen,1 Sixiang Cheng,1 Huilan Xu1

ABSTRACT

Objective To explore the association between sepsis and retinopathy of prematurity (ROP) in premature infants.

Design A systematic review and meta-analysis.

Data sources We performed a systematic search of PubMed, the Cochrane Library and Embase from 1 January, 2000, to 1 January, 2018, with no language restrictions and reported the relationship between sepsis and ROP.

Eligibility criteria Original observational studies, including cohort studies and case-control studies.

Data extraction and synthesis Two reviewers independently completed the study selection and data extraction. The OR and corresponding 95% CI were used to measure the risk of sepsis in patients with ROP. The heterogeneity between studies was evaluated using Cochrane’s Q test and the I² statistic. The Newcastle-Ottawa Scale was adopted to evaluate the quality of each of the included studies, and the Grading of Recommendations Assessment, Development and Evaluation approach was used to assess the quality of the evidence.

Results Sixteen studies with a total sample size of 12,466 premature infants and 2,494 cases of ROP were included in this meta-analysis. Adjusted analysis showed that sepsis was closely related to any stage of ROP (OR = 1.57, 95% CI 1.31 to 1.89) and severe stage of ROP (OR = 2.33, 95% CI 1.21 to 4.51) in premature infants, with 56.3% and 81.8% heterogeneity, respectively. Subgroup analyses showed that heterogeneity was obvious in prospective studies of any stage of ROP (I² = 81.8%, p = 0.001). In a sensitivity analysis, we found that removing any single study did not significantly change the overall effect value. The quality of the evidence was rated as low for both any stage of ROP and severe stage of ROP.

Conclusions Sepsis increases the risk of ROP in preterm infants. However, considering that all included studies are observational and causality can rarely be established, additional evidence is needed to substantiate this finding and provide advice for practice.

INTRODUCTION

Retinopathy of prematurity (ROP) is a vascular proliferation eye disease that affects premature infants and always leads to visual impairment, strabismus and blindness.1 ROP has emerged as one of the leading causes of blindness among children worldwide.2 The development of neonatal care has improved the survival rate of extremely preterm infants, but it has also increased the incidence of ROP. In a prospective study conducted by Al-Essa et al,3 64.5% of preterm infants with birth weight (BW) < 1501 g developed ROP. In a retrospective study in Saudi Arabia, ROP was diagnosed in 56% of infants with gestational age (GA) < 36 weeks, and 15% of those patients were in stage 3 of the disease (severe ROP). In a population-based study in Sweden,4 34.5% of infants with GA < 27 weeks had severe ROP, and only 19.3% of those affected infants were treated. Different incidence rates have been reported in research from Australia,5 Canada,6 Japan7 and China.8 ROP continues to be a challenge to neonatologists and ophthalmologists, and it is vital to screen for the causes of ROP in a timely manner.

Neonatal sepsis is defined as a blood infection that occurs in infants under 90 days old, including bacterial and fungal infections. Early-onset sepsis occurs in the first week after birth, whereas late-onset sepsis occurs after 1 week and before 3 months of age. Neonatal sepsis has non-specific signs and symptoms that contribute to morbidity and mortality among preterm infants. A recent systematic review estimated that there were 16...
3.0 million cases of sepsis in neonates around the world, with mortality ranging from 11% to 19%. Sepsis not only poses a direct risk of death but also damages organs and tissues in neonates.

Many studies have demonstrated that sepsis has a close relationship with the occurrence of ROP. According to Al-Essa et al., the incidence of ROP in preterm infants with sepsis was 3.5 times as high as in those without sepsis (OR = 3.50, 95% CI 1.02 to 12.2). Arza et al. found that sepsis was independently associated with the development of severe ROP in infant inpatients (OR = 6.86, 95% CI 3.14 to 14.99). Thomas et al. reported analogous results in their study (OR = 1.35, 95% CI 1.16 to 1.67). However, Sabzehei et al. and Lin et al. concluded that sepsis status was not significantly different between premature infants with and without threshold ROP (p>0.05).

Considering the severe outcome of ROP and the high morbidity of sepsis, we sought to address the disagreement of several previous studies in a larger pooled sample size by conducting this meta-analysis to explore the link between sepsis and ROP.

**METHODS**

According to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA), we developed a prospective protocol that detailed our research process, including the objectives, literature search strategies, inclusion and exclusion criteria, primary outcome and data analysis. This study adheres to PRISMA guidelines, and the PRISMA checklist is shown in online supplementary table S1.

**Literature search strategy**

We searched PubMed, the Cochrane Library and Embase for studies published from 1 January, 2000, to 1 January, 2018, using a systematic search strategy that removed duplicate titles. The detailed search strategy for this study can be found in the online supplementary table S2. The search terms used the keywords of ‘sepsis’ OR ‘neonatal sepsis’ OR ‘septic’ OR ‘septicemia’ OR ‘risk factors’ AND ‘premature retinopathy’ OR ‘ROP’]. We used a combination of free words and Medical Subject Headings (MeSH) terms to search, and the final search strategy was determined by multiple pre-searches without language restrictions. Moreover, we manually searched for some eligible original documents, reviews and related articles to compensate for the deficiency of the electronic search. If multiple studies reported the same results, the latest and most complete study was selected.

**Study selection and data extraction**

The inclusion criteria for the literature included the following: (1) Original study involving the relationship between sepsis and ROP. (2) Diagnosis of ROP based on an ophthalmoscopic examination performed by ophthalmologists or neonatologists. (3) GA at birth <37 weeks. (4) Provision of original data such as the OR and 95% CI or data that can be converted into the OR and 95% CI. (5) Total sample size >50. The exclusion criteria were as follows: (1) No distinction between the absence of ROP and mild ROP. (2) Duplicated reports, review articles, animal studies and editorial letters. Two reviewers (XFW and KT) independently screened the search results and determined the final list of studies to be included. If there were disagreements between their decisions, a third reviewer (HLX) made the final decision. The information we extracted for each study included the first author, year of publication, country of origin, inclusion criteria of participants, sample size, study design, literature quality score and confounding factors controlled.

**Quality assessment**

We used the Newcastle-Ottawa Scale (NOS), recommended by the Cochrane Manual, to evaluate the quality of the included studies. This scale consists of three main components: selection of study subjects, comparison between study groups and evaluation of outcomes. The maximum total score of this scale is nine points, and studies scoring six points or above are considered high quality. XFW and KT independently scored all items, and HLX acted as the arbiter if there were disagreements.

**Outcomes**

The outcome in this meta-analysis was the association between sepsis and ROP, and ROP was classified as any stage of ROP (stages 1 to 5) and severe stage of ROP (stages 3 to 5) according to the data provided by the studies. The association between sepsis and ROP was expressed as the OR of sepsis associated with ROP. We obtained the ORs and corresponding 95% CIs from most of the included studies. When those values were not directly available, we calculated the OR and 95% CI using the coefficient estimates and standard errors mentioned in the text.

**Statistical analysis**

This meta-analysis was conducted using Stata/SE 12.0 (College Station, Texas: StataCorp LP). Outcomes were assessed by pooled OR among the cohort studies, and the corresponding 95% CIs were calculated by a fixed-effects model or a random-effects model. Heterogeneity between studies was explored by Cochran’s Q test and the I² statistic, where p<0.1 or I²>50% was considered evidence of statistical heterogeneity, and we used a random-effects model for subsequent analysis. In contrast, p>0.1 or I²<50% was considered low heterogeneity, and a fixed-effects model was used. Predefined subgroup analyses were conducted to explore the sources of heterogeneity and to obtain the adjusted ORs by GA (<34 weeks or <37 weeks), BW (<1.5 kg or <2.0 kg), study location (Asia, Africa, USA or Europe), study design (prospective or retrospective) and year of publication (2000~2010 or 2011~2018). Potential publication bias was detected by the combined use of funnel plots and Egger’s test. We also conducted a sensitivity analysis by assessing the changes in the OR and 95% CI after removing any single study. The OR we
selected was the adjusted OR, and p<0.05 was considered statistically significant.

Grading the evidence
Based on the outcomes of the systematic review, XFW and KT independently using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach to determine the quality of the evidence. The quality of the evidence was rated as high, moderate, low or very low. Since all of the studies included in this meta-analysis were observational studies (including cohort and case-control studies), the quality of the evidence was initially defined as low. The rating can be decreased to very low if serious or very serious issues are noted in connection with risk of bias, inconsistency of results, indirectness of evidence, imprecision or publication bias. However, upgrading may be warranted in observational studies if the magnitude of the treatment effect is large (Relative Risk (RR) >2 or RR <0.5) or very large (RR >5 or RR <0.2), if there is evidence of a dose-response relation or if all plausible biases would decrease the magnitude of an apparent treatment effect. Therefore, the quality of the evidence can range from very low to high.

Patient and public involvement
Our research is based on previously published studies. Patients were not directly involved in the design, implementation or analysis of this study. We will disseminate our findings through the journal’s public access.

RESULTS
Search results
Our preliminary search located 509 search records of candidate studies. After browsing the title, abstract and full text, we identified a total of 16 eligible studies with full text and entered them into the data analysis (figure 1).

Characteristics and quality of the included studies
The characteristics of the included studies were shown in table 1. These studies were published from 2000 to 2018 and came from five continents: seven studies were from Asia, four from USA, two each from Africa and Europe and one from Oceania. Of the studies, 11 explored the association between sepsis and any stage of ROP, and six examined the relationship between sepsis and severe stage of ROP. The sample sizes in these studies varied from 110 to 5718. The participants were mainly from the intensive care units, neonatal intensive care units and neonatal centres of local hospitals. The inclusion criteria for premature infants varied considerably: the GA criteria ranged from <28 weeks to <37 weeks, and only 12 studies provided the specific BW range. Most included studies reported the multivariable-adjusted OR and corresponding 95% CI, although one study provided only univariate analysis outcomes. There were eight prospective cohort studies, seven retrospective cohort studies and one nested case-control study, which also came from an institutional retrospective cohort. All included studies had reasonably well-matched groups that appeared to represent the same populations. Fifteen studies provided confounding factors that were controlled, 13 studies reported adequate follow-up to observe the occurrence of the disease and nine studies reported the rate of follow-up or loss to follow-up. The NOS scores of these studies ranged from 5 to 9. A total of 15 studies could be identified as high-quality studies because they scored 6 points or above. Agreement between the two reviewers was 95% for study selection and 93% for quality assessment. Detailed information on the quality assessment is shown in online supplementary table S3.

Sepsis and any stage of ROP
Eleven studies involving a total of 5388 participants reported adjusted ORs for association between sepsis and any stage of ROP. Considering all these adjusted ORs combined, sepsis was associated with a significant risk of any ROP among premature infants in the random-effects model (OR = 1.57, 95% CI 1.31 to 1.89). Moderate heterogeneity was detected (I²=56.3%, p=0.011) (figure 2).

Sepsis and severe stage of ROP
Six studies including a total of 7660 premature infants provided ORs for the severe stage of ROP and were combined in this meta-analysis. Figure 3 shows the combined effect from the random-effects model. The pooled OR was 2.33 (95% CI 1.21 to 4.51), with evidence of substantial heterogeneity (I²=81.8%, p<0.001). Both

---

Figure 1 Flow diagram of included/excluded studies. A total of 509 documents were found in the initial search. After removing duplicates, reading abstracts and full texts and evaluating the quality of the articles, 16 eligible studies were included and analysed.
### Table 1  Characteristics of included studies

| Study            | Year | Country | Study design | Patient No/case | Adjusted OR (95% CI) | NOS score | Screening criteria | Adjustments                  |
|------------------|------|---------|--------------|-----------------|----------------------|-----------|-------------------|------------------------------|
| Kim et al         | 2004 | Korea   | Retrospective | 390/81          | 1.76 (0.90 to 3.50)  | 6         | GA ≥ 28 weeks     | BW ≤ 1500 g                  |
| Rao et al         | 2013 | India   | Prospective  | 282/61          | 0.94 (0.32 to 2.79)  | 8         | GA ≥ 32 weeks     | BW ≤ 1500 g; GA; BW; surfactant; apnea; IPPV; RBC transfusion |
| Abdel et al       | 2012 | Egypt   | Prospective  | 172/33          | 1.25 (1.08 to 1.46)  | 5         | GA ≥ 32 weeks     | BW ≤ 1500 g                  |
| Al-Essa et al     | 2000 | Kuwait  | Prospective  | 234/34          | ROP: severe stage 3.50 (1.02 to 12.20) | 9         | BW < 1501 g       | BW; high concentration of oxygen therapy |
| Reyes et al       | 2017 | Oman    | Retrospective | 171/69          | ROP: any stage 7.47 (1.21 to 46.05) | 7         | GA ≥ 32 weeks     | GA; BW; duration of NCPAP; duration of oxygen therapy |
| Lundgren et al    | 2017 | Australia | Retrospective | 227/25          | ROP: severe stage 3.01 (1.54 to 7.85) | 8         | GA < 28 weeks     | GA; postnatal age            |
| Gonçalves et al   | 2014 | Brazil  | Prospective  | 110/49          | ROP: any stage 1.99 (1.45 to 2.40) | 8         | GA ≥ 32 weeks     | BW ≤ 1500 g                  |
| Mohamed et al     | 2013 | USA     | Retrospective | 582/170/48      | ROP: any stage 1.20 (0.78 to 1.82); severe stage 1.76 (0.92 to 3.40) | 7         | GA ≥ 32 weeks     | BW ≤ 1500 g; GA; hyperglycaemia days; ventilator days; IVH; PDA; neonatal steroids |
| Hadi             | 2013 | Egypt   | Prospective  | 152/52          | ROP: any stage 1.47 (1.17 to 1.85) | 9         | GA < 28 weeks     | BW ≤ 1500 g; NCPAP; IMV; NIHB; PDA; IVH; RBC transfusion |
| Chen et al        | 2010 | USA     | Nested case-control | 622/293 | ROP: any stage 2.10 (1.40 to 3.20) | 7         | GA > 30 weeks     | BW ≤ 1501 g; BW; GA; multiple birth; high-frequency ventilation; oxygen at 28 days; PDA; race |
| Ebrahim et al     | 2010 | Iran    | Retrospective | 173/33          | ROP: any stage 0.60 (0.04 to 10.39) | 6         | GA ≥ 37 weeks     | Sex; BW; multiple birth; oxygen therapy; blood transfusion; phototherapy; ARDS |
| van Sorge et al   | 2014 | Netherlands | Prospective | 1380/302        | ROP: any stage 1.30 (0.90 to 1.70) | 9         | GA ≥ 32 weeks     | BW ≤ 1500 g                  |
| Huang et al       | 2015 | China   | Prospective  | 5718/698        | ROP: severe stage 0.92 (0.75 to 1.14) | 8         | VLBW infant      | Pre-eclampsia; GA; BW; caesarean section; sex; SGA; Apgar score; RDS; transfusion; PDA |
| Wani et al        | 2010 | Kuwait  | Retrospective | 599/47          | ROP: severe stage 3.27 (1.51 to 7.05) | 7         | GA ≥ 34 weeks     | BW ≤ 1501 g; BW; surfactant use |
| Aydemir et al     | 2011 | Turkey  | Prospective  | 300/21          | ROP: severe stage 5.36 (1.58 to 18.28) | 9         | BW ≤ 1500 g       | BW; mechanical ventilation; PDA |
| Port et al        | 2014 | USA     | Retrospective | 1354/526        | ROP: any stage 2.47 (1.50 to 4.06) | 7         | GA ≥ 30 weeks     | BW ≤ 1500 g; BW; GA; assisted conception; bronchopulmonary dysplasia; race |

ARDS, acute respiratory distress syndrome; BW, birth weight; GA, gestational age; IMV, intermittent mechanical ventilation; IPPV, invasive positive pressure ventilation; IVH, intraventricular haemorrhage; NCPAP, nasal continuous positive airway pressure; NIHB, neonatal indirect hyperbilirubinaemia; NOS, Newcastle Ottawa scale; PDA, patent ductus arteriosus; RBC, red blood cell; ROP, retinopathy of prematurity; SGA, small for gestational age; VLBW infant: very low birth weight.
research results demonstrated that sepsis was closely related to the development of ROP in premature infants.

Subgroup analysis

As shown in table 2, in any stage of ROP, the heterogeneity between GA, BW and geographical subgroups was significantly less than their combined effects, respectively, suggesting that these categories could explain the potential heterogeneity. GA <34 weeks (OR=1.70, 95% CI 1.39 to 2.70), and BW <1.5 kg (OR=1.66, 95% CI 1.38 to 2.01) showed an elevated risk in any stage of ROP. Research published in 2000–2010 (OR=1.96, 95% CI 1.38 to 2.79) and studies conducted in the USA also showed an increased risk of any ROP (OR=1.87, 95% CI 1.43 to 2.45). Moderate heterogeneity was found in the prospective cohort studies ($I^2=62.1\%, p=0.032$), and studies published in 2011–2018 were responsible for most of the heterogeneity ($I^2=63.4\%, p=0.008$). The results for severe stages of ROP were different, and it was difficult to identify sources of heterogeneity, since there were few studies that could be combined.

Publication bias and sensitivity analysis

There was no evidence of asymmetry in the funnel plots (figure 4), and Egger’s test showed $t=1.12$ ($p=0.290$). Considering the funnel plots and Egger’s test, we concluded that there was no apparent publication bias among the studies that examined all stages of ROP. However, publication bias was not assessed in studies on the severe stage of ROP because there was insufficient power to evaluate funnel plot asymmetry and small-study effects ($<10$ studies included).

When we excluded Abdelet’s study, which had the lowest NOS score, the pooled OR was 1.66 (95% CI 1.37 to 2.01) in any stage of ROP. When we removed any single study in any stage of ROP and severe stage of ROP, the pooled ORs ranged from 1.50 (95% CI 1.25 to 1.79) to 1.66 (95% CI 1.37 to 2.01) and from 2.20 (95% CI 1.09 to 4.45) to 2.74 (95% CI 1.87 to 4.02), respectively. No obvious change was found in the pooled ORs, and each was statistically significant.

GRADE assessment

The quality of evidence was rated as low for the outcomes of association between sepsis and any stage of ROP, having been upgraded by one point because all plausible biases would decrease the magnitude of an apparent treatment effect, and been downgraded because moderate heterogeneity between studies was detected ($I^2=56.3\%, p=0.011$) and could not be fully explained. Meanwhile, the quality of the evidence was also rated as low for the relationship between sepsis and severe stage of ROP: the magnitude of the effect was large (OR >2 based on consistent evidence from at least two studies, with no plausible confounders), which added one point, but there was evidence of substantial heterogeneity between studies that could not be explained ($I^2=81.8\%, p<0.001$), which subtracted one point, leaving the final score at two points for a quality level of ‘low’. A summary of the GRADE assessment is shown in online supplementary table S4.

DISCUSSION

The prevalence of ROP and its association with sepsis are great challenges worthy of global attention. To our knowledge, this is the first meta-analysis to assess the independent risk of sepsis in ROP. Our research applied strict inclusion criteria. According to the International Classification of Retinopathy of Prematurity, ROP is divided...
into 5 stages, of which stages 1 to 2 are defined as mild ROP and stages 3 to 5 are defined as severe ROP. The former does not require treatment, while the latter does.10 To ensure the homogeneity of these studies, we included only those that compared a group without ROP to a group with ROP, with or without restrictions on severity. Any study that was divided into ‘no treatment’ (no ROP and mild ROP) versus ‘treatment’ (severe ROP) was excluded. After controlling for confounding factors such as GA and BW and adopting adjusted ORs, we speculated that sepsis distinctly increases the overall risk of ROP and the risk of severe ROP among preterm infants.

How does sepsis induce ROP or increase its severity? Successful trials have yielded some possible explanations, which can be summarised as follows: (1) The pathogenic microorganisms and their toxins cause sepsis-related damage in vascular endothelial cells, making white blood cells readily adhere to the blood vessel walls and form microthrombi in the small blood vessels of the retina; these microthrombi lead to blood vessel obstruction.

### Table 2 Subgroup meta-analysis and analysis of heterogeneity

| Subgroup                     | Number of studies | Patient No/case | Adjusted OR (95% CI) | I^2 (%) | P value |
|------------------------------|-------------------|-----------------|-----------------------|---------|---------|
| Any stage of ROP             |                   |                 |                       |         |         |
| Gestational age              |                   |                 |                       |         |         |
| ≤34 weeks                    | 8                 | 4761/1542       | 1.70 (1.39 to 2.07)   | 49.8    | <0.001  |
| <37 weeks                    | 3                 | 627/127         | 1.24 (1.07 to 1.44)   | 0       | 0.005   |
| Birth weight                 |                   |                 |                       |         |         |
| ≤1.5 kg                      | 7                 | 4590/1473       | 1.66 (1.38 to 2.01)   | 46.9    | <0.001  |
| ≤2.0 kg                      | 4                 | 798/196         | 1.34 (0.75 to 2.40)   | 29.3    | 0.323   |
| Geographical location        |                   |                 |                       |         |         |
| Asian                        | 4                 | 1016/244        | 1.66 (0.79 to 3.49)   | 29.2    | 0.183   |
| Africa                       | 2                 | 324/85          | 1.32 (1.14 to 1.54)   | 25.5    | <0.001  |
| USA                          | 4                 | 2668/1038       | 1.87 (1.43 to 2.45)   | 49.5    | <0.001  |
| Europe                       | 1                 | 1380/302        | 1.30 (0.95 to 1.79)   | -       | 0.106   |
| Study design                 |                   |                 |                       |         |         |
| Prospective                  | 5                 | 2096/497        | 1.45 (1.18 to 1.77)   | 62.1    | <0.001  |
| Retrospective                | 6                 | 3292/1172       | 1.86 (1.32 to 2.64)   | 41.5    | <0.001  |
| Year of publication          |                   |                 |                       |         |         |
| 2000–2010                    | 3                 | 1185/407        | 1.96 (1.38 to 2.79)   | 0       | <0.001  |
| 2011–2018                    | 8                 | 4203/1262       | 1.52 (1.24 to 1.86)   | 63.4    | <0.001  |
| Severe stage of ROP          |                   |                 |                       |         |         |
| Gestational age              |                   |                 |                       |         |         |
| ≤34 weeks                    | 5                 | 7426/839        | 2.20 (1.09 to 4.45)   | 83.7    | 0.028   |
| <37 weeks                    | 1                 | 234/34          | 3.50 (1.01 to 12.10)  | -       | 0.048   |
| Geographical location        |                   |                 |                       |         |         |
| Asian                        | 3                 | 6551/779        | 1.99 (0.70 to 5.67)   | 85.2    | 0.196   |
| Oceania                      | 1                 | 227/25          | 3.01 (1.33 to 6.80)   | -       | 0.008   |
| Europe                       | 1                 | 300/21          | 5.36 (1.58 to 18.23)  | -       | 0.007   |
| USA                          | 1                 | 582/48          | 1.76 (0.92 to 3.38)   | -       | 0.090   |
| Study design                 |                   |                 |                       |         |         |
| Prospective                  | 3                 | 4062/1578       | 2.30 (0.65 to 8.14)   | 83.0    | 0.195   |
| Retrospective                | 3                 | 1408/120        | 2.46 (1.61 to 3.76)   | 0       | <0.001  |
| Year of publication          |                   |                 |                       |         |         |
| 2000–2010                    | 2                 | 833/81          | 3.33 (1.73 to 6.41)   | 0       | <0.001  |
| 2011–2018                    | 4                 | 6827/792        | 1.98 (0.93 to 4.23)   | 82.4    | 0.078   |

ROP, retinopathy of prematurity.
and abnormal growth factor levels, might also contribute to the increased risk of ROP in preterm infants. These factors have not been taken into account in the studies included in this review; this omission from the original studies may cause our results to deviate from the real effects. In addition, a total of 12 studies in this meta-analysis included premature infants with BW less than 1500 g. Therefore, the combined effect value may represent this type of premature infant, not all premature infants.

As mentioned above, sepsis can be classified as early or late and as bacterial or fungal. Since most of the original studies performed fundus examinations for ROP screening 4–6 weeks after birth, only two studies27,28 provided findings that might include late-onset sepsis. It is difficult for us to distinguish whether these patients had early-onset or late-onset sepsis. Moreover, all studies showed that the diagnosis of sepsis was based on clinical blood culture, but they did not make a clear distinction between the pathogens. Hussain et al found that culture-positive sepsis of any aetiology was significantly associated with ROP.29 Manzoni et al found that fungal (but not bacterial) sepsis was independently associated with ROP, but only in VLBW neonates and only with threshold ROP.30 Bharwani also reported that systemic fungal infection (SFI) was associated with the development of all degrees of ROP in VLBW infants.31 However, the current studies and review do not address the mechanism of the association between SFI and ROP or prove any cause and effect; therefore, this association needs to be studied in a larger population before any conclusions can be drawn.

In a subgroup analysis, we found that infants born with shorter GA and lighter BW were more likely to develop ROP. This finding is consistent with the results of most previous studies, which confirmed that short GA and low BW were independent risk factors for ROP, especially for VLBW infants.33–37 Some researchers even believed that BW might be a more important criterion than GA for the screening of ROP.38 Preterm infants, regardless of GA or whether their BW was below the normal range, were much more susceptible to infection than full-term babies and often lacked the capacity to overcome it, which could induce or exacerbate ROP in the event of a severe infection that leads to sepsis.39 In addition, due to the incomplete development of retinal blood vessels in preterm infants, it is easy to induce the formation of new retinal blood vessels and fibrous tissue, which may be a very common cause of ROP.

This study also showed regional differences in the relationship between sepsis and any stage of ROP, with the risk being highest in the USA, second highest in Asia and lowest in Europe, with Africa having a slightly higher risk than Europe. This phenomenon might be associated with ethnicity. Aralikatti et al reported that Asian and Black premature infants had a higher risk of developing

Figure 4 Funnel plots of the association between sepsis and any stage of ROP. The solid line represents the overall pooled estimate for all included studies. Dashed lines represent 95% CIs. Egger’s test gave a result of 0.20, p=0.06. ROP, retinopathy of prematurity.
threshold ROP compared with White infants, and similar outcomes were reported by Ng et al. The former believe that the differential risk may be related to pigmentation, because animal models of ROP have shown that pigmented strains are more susceptible to ischaemia-induced retinal neovascularization than albino strains. The latter group holds that this difference was because of the better survival of Asian infants, as preterm infants in these ethnic groups are more likely to survive and hence develop severe ROP than preterm infants of other ethnicities. Both groups agreed that Asian and African preterm infants needed more treatment than White infants. However, according to Darlow et al, premature infants born to Asian mothers had higher risk than White infants, but this difference did not exist in the adjusted analysis. Chen et al also found that there was no significant association between ROP and ethnicity. Thus, further evidence is needed to explain the specific mechanisms and causes of the different rates of ROP prevalence among different ethnic groups.

The overall quality of the evidence was assessed by the GRADE approach, which showed low quality for the relationship between sepsis and both any stage of ROP and severe stage of ROP; thus, we have limited confidence in the estimation of both effect value. Since few studies could be combined for severe ROP, some potential publication bias may have gone undetected and caused the level of evidence to be overestimated. Further study is likely or very likely to have an important impact on our confidence in the estimated effect and may change our estimate.

This meta-analysis has the following limitations. First, the number of studies included is limited, and all original articles are observational studies, from which causality can rarely be established. Second, different inclusion criteria in each study and inaccurately specified criteria in a few studies might have influenced the pooled effect. Third, multiple testing due to the number of subgroup analyses could have led to false-positive results. Finally, although we did not use language restrictions in the search strategy, the final articles included were mainly in English. These limitations must be taken into account when evaluating the final outcomes.

CONCLUSION

Our meta-analysis shows that sepsis is closely related to the development of any stage of ROP and severe stage of ROP. This provides valuable information for neonatologists and ophthalmologists regarding the treatment of preterm infants. However, considering the shortcomings of this study, our results need to be interpreted cautiously. More evidence is needed to validate our findings and provide constructive advice for clinical practice, and well-designed trials are needed to provide a clearer explanation of the mechanisms and interrelationships between ROP and different types of sepsis. Strengthening the screening and intervention process for sepsis in preterm infants and preventing them from developing blindness is a global priority that depends on the joint efforts of researchers and clinicians worldwide.

REFERENCES

1. Abirshimi M, Maemori GA, Boskabadi H, et al. Incidence and risk factors of retinopathy of prematurity in mashhad, northeast iran. Iran Red Crescent Med J 2013;15:229–33.
2. Binkhathlan AA, Almahmoud LA, Saleh MJ, et al. Retinopathy of prematurity in Saudi Arabia: incidence, risk factors, and the applicability of current screening criteria. Br J Ophthalmol 2008;92:167–9.
3. Al-Essa M, Azad RV, Rashwan N. Threshold stage of retinopathy of prematurity: maternal and neonatal risk factors. Ann Saudi Med 2000;20:129–31.
4. Stoltz Sjöström E, Lundgren P, Ohlund I, et al. Low energy intake during the first 4 weeks of life increases the risk for severe retinopathy of prematurity in extremely preterm infants. Arch Dis Child Fetal Neonatal Ed 2016;101:F108–F13.
5. Lundgren P, Athkarisamy SE, Patole S, et al. Duration of anemia during the first week of life is an independent risk factor for retinopathy of prematurity. Acta Paediatrica 2017.
6. Thomas K, Shah PS, Canning R, et al. Retinopathy of prematurity: Risk factors and variability in Canadian neonatal intensive care units. J Neonatal Perinatal Med 2015;8:207–14.
7. Enomoto H, Miki A, Matsumiya W, et al. Evaluation of oxygen supplementation status as a risk factor associated with the development of severe retinopathy of prematurity. Ophthalmologica 2015;234:135–8.
8. Li WL, He L, Liu XH, et al. Analysis of risk factors for retinopathy of prematurity. Int J Ophthalmol 2011;4:631–3.
9. Fleischmann-Szrucek C, Goldfarb DM, Schlattmann P, et al. The global burden of paediatric and neonatal sepsis: a systematic review. Lancet Respir Med 2018;6:223–30.
10. Araz-Ersan B, Kir N, Akarcay K, et al. Epidemiological analysis of retinopathy of prematurity in a referral centre in Turkey. The British journal of ophthalmology 2013;97:15–17.
11. Sabzehei MK, Afjeh SA, Dastjani Farahani A, et al. Retinopathy of prematurity: incidence, risk factors, and outcome. Arch Iran Med 2013;16:507–12.
12. Lin HJ, Lin CC, Tsai SW, et al. Risk factors for retinopathy of prematurity in very low birth-weight infants. J Chin Med Assoc 2003;66:662–8.
13. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009;339:b2700.
14. Margulis AV, Pladevall M, Riera-Guardia N, et al. Quality assessment of observational studies in a drug-safety systematic review, comparison of two tools: the Newcastle-Ottawa Scale and the RTI item bank. Clin Epidemiol 2014;6:359–68.
15. Fan X, Lin T, Xu K, et al. Laparoscopic single-site nephrectomy compared with conventional laparoscopic nephrectomy: a systematic review and meta-analysis of comparative studies. Eur Urol 2012;62:601–12.
16. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ* 2008;336:924–6.

17. Abdel HA, Mohamed GB, Ohman MF. Retinopathy of Prematurity: A Study of Incidence and Risk Factors in NICU of Al-Azhar University Hospital in Egypt. *J Clin Neonatol* 2012;1:76–81.

18. Quinn G, International Committee for the Classification of Retinopathy of Prematurity. The International Classification of Retinopathy of Prematurity revisited. *Arch Ophthalmol* 2005;123:991–9.

19. Joussen AM, Poulaki V, Le ML, et al. A central role for inflammation in the pathogenesis of diabetic retinopathy. *Faseb J* 2004;18:1450–2.

20.Uskow-Pfuike M. VEGF signaling through NADPH oxidase-derived ROS. *Antioxid Redox Signal* 2007;9:731–9.

21. Hellwig-Etinger T, Rudowicz K, Metzen E, et al. Interleukin-1beta and tumor necrosis factor-alpha stimulates DNA binding of hypoxia-inducible factor-1. *Blood* 1999;94:1561–7.

22. McMahon S, Charbonneau M, Grandmont S, et al. Transforming growth factor beta1 induces hypoxia-inducible factor-1 stabilization through selective inhibition of PHD2 expression. *J Biol Chem* 2006;281:24171.

23. Hardy P, Beauchamp M, Sennlaub F, et al. New insights into the retinal circulation: inflammatory lipid mediators in ischemic retinopathy. *Prostaglandins Leukot Essent Fatty Acids* 2005;72:301–25.

24. Yang CY, Lien R, Yang PH, et al. Analysis of incidence and risk factors of retinopathy of prematurity among very-low-birth-weight infants in North Taiwan. *Pediatr Neonatol* 2011;52:321–6.

25. Hellwig-Etinger T, Rudowicz K, Metzen E, et al. Interleukin-1beta and tumor necrosis factor-alpha stimulates DNA binding of hypoxia-inducible factor-1. *Blood* 1999;94:1561–7.

26. Bardin C, Zielkowitz P, Papageorgiou A. Outcome of small-for-gestational age and appropriate-for-gestational age infants born before 27 weeks of gestation. *Pediatics* 1997;100:E4.

27. Reyes ZS, Al-Muallaed SW, Bataclan F, et al. Retinopathy of prematurity: revisiting incidence and risk factors from Oman compared to other countries. *Oman J Ophthalmol* 2017;10:26–32.

28. Chien M, Citi A, McCabe F, et al. Infection, oxygen, and immunity: interacting risk factors for retinopathy of prematurity. *Neonatology* 2011;99:125–32.

29. Wani VB, Kumar N, Sabti K, et al. Results of screening for retinopathy of prematurity in a large nursery in Kuwait: Incidence and risk factors. *Indian J Ophthalmol* 2010;58:204–8.

30. Hussain N, Clive J, Bhandari V. Current incidence of retinopathy of prematurity, 1989–1997. *Pediatrics* 1999;104:e26.

31. Manzon P, Maastrti A, Leonessa M, et al. Fungal and bacterial sepsis and threshold ROP in preterm very low birth weight neonates. *J Perinatol* 2006;26:23–30.

32. Bharwani SK, Dhanireddy R. Systemic fungal infection is associated with the development of retinopathy of prematurity in very low birth weight infants: a meta-review. *J Perinatol* 2008;28:61–6.

33. 최성호. 항문암. Incidence and Risk Factors of Retinopathy of Prematurity in Extremely Low Birth Weight and Very Low Birth Weight Infants. *Journal of the Korean Ophthalmological Society* 2006;47:918–26.

34. Kavurt S, Yücel H, Hekimoğlu E, et al. Retinopathy of prematurity (ROP): Cases and risk factors. *Cocuk Sagligi ve Hastaliklari Dergisi* 2007;28:77–80.

35. Shah V, Chiang J, Chung S, et al. To determine the incidence, risk factors and need for surgery for retinopathy of prematurity (ROP) among Very-Low-Birth-Weight (VLBW) infants weighing. *Archives of Disease in Childhood* 2014;99:A465.

36. Akkoyun I, Oto S, Yilmaz G, et al. Risk factors in the development of mild and severe retinopathy of prematurity. *J Aapos* 2006;10:449–53.

37. Bas AY, Demirel N, Koc E, et al. Incidence, risk factors and severity of retinopathy of prematurity in Turkey (TR-ROP study): a prospective, multicentre study in 69 neonatal intensive care units. *Br J Ophthalmol* 2010;94:416–20.

38. Araz-Ensar B, Kuk R, Akarcay K, et al. Epidemiological analysis of retinopathy of prematurity in a referral centre in Turkey. *Br J Ophthalmol* 2013;97:15–17.

39. Quiroga A, Moxon S. Preventing sight-threatening ROP: the role of nurses in reducing the risk. *Community Eye Health* 2017;30:53–4.

40. Aralikatti AK, Mitra A, Denniston AK, et al. Is ethnicity a risk factor for severe retinopathy of prematurity? *Arch Dis Child Fetal Neonatal Ed* 2010;95:F174–6.

41. Ng YK, Fielder AR, Shaw DE, et al. Epidemiology of retinopathy of prematurity. *Lancet* 1988;2:1235–8.

42. Kim TI, Sohn J, Pi SY, et al. Postnatal risk factors of retinopathy of prematurity. *Paediatr Perinat Epidemiol* 2004;18:130–4.

43. Rao KA, Purkayastha J, Hazarka M, et al. Analysis of prenatal and postnatal risk factors of retinopathy of prematurity in a tertiary care hospital in South India. *Indian J Ophthalmol* 2013;61:640–4.

44. Gonçalves E, Nässer LS, Martelli DR, et al. Incidence and risk factors for retinopathy of prematurity in a Brazilian reference service. *Sao Paulo Med J* 2014;132:85–91.

45. Mohamed M, Murray JC, Daple JM, et al. Hyperglycemia as a risk factor for the development of retinopathy of prematurity. *BMC Pediatr* 2013;13:78.

46. Hadi AM, Hamdy IS. Correlation between risk factors during the neonatal period and appearance of retinopathy of prematurity in preterm infants in neonatal intensive care units in Alexandria, Egypt. *Clin Ophthalmol* 2013;7:831–7.

47. Ebrahim M, Ahmad RS, Mohammad M. Incidence and risk factors of retinopathy of prematurity in Babol, North of Iran. *Ophthalmic Epidemiol* 2010;17:166–70.

48. van Sorge AJ, Termote JU, Kerkhoff FT, et al. Nationwide inventory of risk factors for retinopathy of prematurity in the Netherlands. *J Pediatr* 2014;164:494–8.

49. Huang HC, Yang H, Chou HC, et al. Preeclampsia and Retinopathy of Prematurity in Very-Low-Birth-Weight Infants: A Population-Based Study. *PloS One* 2015;10:e0143248.

50. Aymemir O, Sarikabadayi YU, Aymemir C, et al. Adjusted poor weight gain for birth weight and gestational age as a predictor of severe ROP in VLBW infants. *Eye* 2011;25:725–9.

51. Port AD, Chan RV, Ong SM, et al. Risk factors for retinopathy of prematurity: insights from outlier infants. *Graefes Arch Clin Exp Ophthalmol* 2014;252:1669–77.